Brought to you by 
Myriad buys Sividon Diagnostics for €35mm plus earn-outs
25 Sep 2020
Executive Summary
Myriad Genetics Inc. acquired molecular oncology testing firm Sividon Diagnostics GMBH for €35mm ($39.1mm) up front plus up to €15mm in performance-based earn-outs.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Myriad buys Sividon Diagnostics for €35mm plus earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice